ClearNote Health

This account is no longer actively managed. Please follow all our activity on the following channels or visit our website: clearnotehealth.com linkedin.com/company/clearn… bsky.app/profile/clearn… Thank you!

ClearNote Health’s Avantect® Multi-Cancer Detection Test Selected as One of Two Noninvasive Blood-Based Technologies for @theNCI’s Vanguard Study. Read the PR: clearnotehealth.com/press-release/…

Did you know that Type 2 Diabetes can increase the risk of pancreatic as well as other cancers? Recently, Dr. Steve Edelman and the Taking Control Of Your Diabetes (@TCOYD) team highlighted the connection between #diabetes and #pancreaticcancer: tcoyd.org/2024/09/the-co…

Avantect Ovarian Cancer Test Receives CPT Code and Preliminary Payment Determination from the Centers for Medicare and Medicaid Services Learn more: clearnotehealth.com/press-release/…

📢 ClearNote Health will be at the 14th World CB & CDx Boston Summit, Sept 3rd-6th. 📍Find us at #Booth35 and learn more about the advantages of the Virtuoso Epigenomics Platform for longitudinal analysis in your translational research. #drugdevelopment #therapyresponse

Join us at #TRICON as Samuel Levy, Chief Scientific Officer, shares how unlocking the full potential of #epigenomics will improve #cancer patient care through early detection: lnkd.in/ggXA78z4

We look forward to presenting @ASCO #GI23. Join @ClearNote Health poster session on Jan,20, 12:00 - 1:30 PM and 4:30-5:30 PM to learn about early detection of #PancreaticCancer using 5hmC-based #liquidbiopsy (abstract 672)

We look forward to providing an update on our progress with the Avantect Pancreatic Cancer Detection Test at #jpm23. Join Dave Mullarkey, CEO, today at 2:30 p.m. PST at the Westin St Francis, Mission Bay room #pancreaticcancer #precisionmedicine #earlydetection

Join Dave Mullarkey, CEO, at #JPM23 for a discussion on our ongoing clinical validation efforts and the commercialization roadmap for The Avantect™ Early #cancer Detection Portfolio. clearnotehealth.com/press-release/…

#NEWS: Bluestar Genomics is now ClearNote Health. Our name has changed, but our goal remains the same – developing non-invasive tests to detect #cancer earlier than existing methods by harnessing the power of #epigenomics. clearnotehealth.com/press-release/… #genomics #precisionmedicine

Today we announced the initiation of one of the largest #PancreaticCancer studies to date using epigenomic approach to enable #earlydetection. Learn more: bluestargenomics.com/press-release/…

Did you know that #diabetes and #PancreaticCancer are linked? Learn more from @diabetesdaily: diabetesdaily.com/blog/theres-a-…

Join us tomorrow for a presentation by @Samuel Levy, Bluestar Genomics Chief Science Officer, at @The Lustgarten Foundation's webinar focused on innovation in early detection of #PancreaticCancer. Register now: lnkd.in/d5rUCKF8 #genomics #cancer #EarlyDetection

Our Chief Science Officer, Samuel Levy, PhD, is presenting at @Lustgarten webinar about #innovation in #earlydetection of #PancreaticCancer Join us on Nov. 16 twitter.com/lustgartenfdn/…

#Immunotherapy can help #lung cancer patients. But, not all patients will respond to the treatment. During #SITC22, on Nov. 10, we present study results demonstrating - for the first time - the potential of 5hmC to predict and monitor Tx effectiveness. lnkd.in/g9n_duc8

We are pleased to mark #Movember2022 with @CR_AACR publication on our research with @UCSFCancer collaborator Dr. Felix Feng to extend understanding on non-invasive diagnosis and monitoring of #ProstateCancer : aacrjournals.org/cancerres/arti…

Anna Bergamaschi, PhD, presented positive results from the validation study of the Pancreatic Cancer Detection Test at #APA22. To learn more about the Bluestar Genomics test availability, visit: lnkd.in/gauvNTtS #genomics #cancer #liquidbiopsy

Today we announced positive results from a validation study for our early pancreatic #cancer detection test and launched a physician experience program to bring the test into clinical use. Learn more about presentation at #APA22: tinyurl.com/3ndpa9n5 #genomics #EarlyDetection

Bluestar Genomics receives CAP. “This a testament to our focus on preparing the company to serve customers around the world, helping millions of patients avoid late-stage, untreatable cancer diagnosis,” said David Mullarkey, CEO. tinyurl.com/2zvk77jh #liquidbiopsy #genomics

New Data at #ESMO22, #AACRPan22, #AGBTPH highlight the expansion of the company's platform, underscoring the feasibility of widespread deployment of 5hmC-based #epigenomics technology for early detection of #cancer & understanding resistance to treatments. businesswire.com/news/home/2022…